{
    "clinical_study": {
        "@rank": "83922", 
        "arm_group": [
            {
                "arm_group_label": "BIOD-238", 
                "arm_group_type": "Experimental", 
                "description": "Subcutaneous injection"
            }, 
            {
                "arm_group_label": "BIOD-250", 
                "arm_group_type": "Experimental", 
                "description": "Subcutaneous injection"
            }, 
            {
                "arm_group_label": "Humalog", 
                "arm_group_type": "Active Comparator", 
                "description": "Subcutaneous injection"
            }
        ], 
        "brief_summary": {
            "textblock": "A Double-blind Study of the Pharmacokinetic Properties of BIOD-238 and BIOD-250 Compared to\n      Humalog\u00ae in Subjects with Type 1 Diabetes"
        }, 
        "brief_title": "Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog\u00ae in Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Type 1 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to assess the speed of absorption of BIOD-238 and BIOD-250\n      compared to Humalog\u00ae.  Secondary objectives are to assess other pharmacokinetic\n      characteristics of BIOD-238 and BIOD-250 compared to Humalog\u00ae, and to evaluate the safety\n      and tolerability of BIOD-238 and BIOD-250 compared to Humalog\u00ae."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: \u226518 to \u226470 years\n\n          -  Body Mass Index: \u226518 and \u226435 kg/m2\n\n          -  Diagnosed with Type 1 Diabetes Mellitus for at least 1 year\n\n        Exclusion Criteria:\n\n          -  Type 2 diabetes mellitus\n\n          -  Serum C-peptide >1.0 ng/mL\n\n          -  HbA1c >10.0%\n\n          -  History of hypersensitivity to any of the components in the study medication\n\n          -  Treatment with any other investigational drug in the last 30 days before dosing.\n\n          -  Current drug or alcohol abuse, or a history of drug or alcohol abuse which in the\n             opinion of the Investigator will impair subject safety, protocol compliance, or\n             interpretation of study results. Caffeine, nicotine or alcohol addiction which might\n             be expected to result in withdrawal symptoms during the course of a study dosing day\n             would fall into this category."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01811849", 
            "org_study_id": "4-102"
        }, 
        "intervention": [
            {
                "arm_group_label": "BIOD-238", 
                "intervention_name": "Insulin LISPRO", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BIOD-250", 
                "intervention_name": "Insulin LISPRO", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Humalog", 
                "intervention_name": "Insulin LISPRO", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin LISPRO", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "diabetes", 
        "lastchanged_date": "March 14, 2013", 
        "number_of_arms": "3", 
        "official_title": "A Double-blind Study of the Pharmacokinetic Properties of BIOD-238 and BIOD-250 Compared to Humalog\u00ae in Subjects With Type 1 Diabetes Including Assessments of Safety and Injection Site Toleration", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Time to 1/2 maximal insulin concentration", 
            "safety_issue": "No", 
            "time_frame": "480 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01811849"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to maximal insulin concentration", 
                "safety_issue": "No", 
                "time_frame": "480 minutes"
            }, 
            {
                "measure": "Time to 1/2 maximal insulin concentration after peak", 
                "safety_issue": "No", 
                "time_frame": "480 minutes"
            }, 
            {
                "measure": "Visual analog scale", 
                "safety_issue": "No", 
                "time_frame": "30 minutes"
            }, 
            {
                "measure": "AUC 0-30 and AUC 0-60", 
                "safety_issue": "No", 
                "time_frame": "60 minutes"
            }
        ], 
        "source": "Biodel", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biodel", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}